THARROS - Commercial study of a new inhaler for COPD. Aborted due to lack of resource and staffing. Attack - Academic study of aspirin for chronic kidney disease. Inherited from the previous provider and completed by NPC. Immunedefence - Academic study of a new nasal spray to reduce respiratory infections in primary care. Inherited from the previous provider and completed by NPC. SAFER - Academic study screening atrial fibrillation with ECG to reduce stroke. Inherited from the previous provider and completed by NPC. OptiZest - Commercial study pilot on personalised dose of Zestril for hypertension. Delivered by NPC and set to expand to full trial in 2025. Duration UTI - Academic study to determine optimal antibiotic therapy for UTIs. In delivery until July 2025. ATEMPT - Academic study of antihypertensive treatment in multimorbidity and polypharmacy. Indigo - Academic study using a wellness survey for people with historic cancer diagnosis. MOVe-NOW - Commercial study of COVID-19 patients contraindicated for the standard antiviral treatment. 5-year study that NPC has just begun.
The NPC Norfolk Research Team has attended and taken part in the following conferences and workshops over the 2024/25 period: • HETT conference (Healthcare Technologies) at ExCel • A 2-day workshop on the Stanford Biodesign innovation process • Clinical Research Practitioners (CRP) event in London • Research Delivery Network (RDN) 10 year anniversary event • East of England Research Conference for Nurses, midwives and Allied Health professionals • Genomics Collaboration event
Norfolk Primary Care - Quality Account 2024/25
29 | Pa g e
Made with FlippingBook - Online catalogs